Active Filter(s):
Details:
Cyrano intends to use the proceeds to advance FLAVOR, its Phase 2, double-blind, randomized clinical trial of CYR-064, an intranasal theophylline spray therapy to treat patients who have lost their sense of smell following recovery from a viral infection.
Lead Product(s): Theophylline
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: CYR-064
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: DeepWork Capital
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 16, 2024